Pfizer agreed to acquire privately held NJ-based InnoPharma for $225M upfront plus up to $135M in milestones, building out a sterile injectables and specialty-injectable pipeline ahead of its 2015 Hospira mega-deal. Closed September 25, 2014.
Did it work? Outcome assessment
Strategic verdict
Partially Achieved
Pipeline outcome
Mixed
Assessment window: 5yr post-close.
Key facts
AnnouncedJul 17, 2014
ClosedSep 25, 2014
Deal value$360M
Deal typeAcquisition/Merger
Therapeutic areaOncology and CNS sterile injectables
IndicationsOncology and CNS sterile injectables
Key assetsSterile injectables development pipeline